Skip to main content

Georgina Arrambide García

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Georgina Arrambide García

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

Caracterización de pacientes con esclerosis múltiple muy activa y evaluación del efecto de tratamientos de alta efectividad en la evolución de su enfermedad.

IP: Georgina Arrambide García
Collaborators: Jordi Rio Izquierdo, Joaquin Castillo Justribo, Mireia Castillo Juarez
Funding agency: Instituto de Salud Carlos III
Funding: 169400
Reference: PI22/01570
Duration: 01/01/2023 - 30/06/2027

Niveles en suero de neurofilamentos de cadena ligera como marcador pronóstico de evolución de la enfermedad y de respuesta al tratamiento en esclerosis múltiple

IP: Georgina Arrambide García
Collaborators: Jordi Rio Izquierdo, Rosalia Horno Ocaña, Cristina Auger Acosta, Joaquin Castillo Justribo, Mireia Castillo Juarez
Funding agency: Instituto de Salud Carlos III
Funding: 110715
Reference: PI19/01590
Duration: 01/01/2020 - 30/06/2024

Estudio de la vía visual en pacientes que presentan un síndrome clínico aislado, utilidad clínica y pronóstica

IP: Angela Vidal Jordana
Collaborators: Dulce María Moncho Rodríguez, Georgina Arrambide García, Joaquin Castillo Justribo, Vanessa Carolina Thonon
Funding agency: Instituto de Salud Carlos III
Funding: 77440
Reference: PI17/02162
Duration: 01/01/2018 - 30/06/2022

Papel de los factores hormonales relacionados con la mujer en el riesgo y pronóstico de la E.M.

IP: Mar Tintore Subirana
Collaborators: Susana Otero Romero, Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Cristina Auger Acosta, Georgina Arrambide García, Alex Rovira Cañellas, Joaquin Castillo Justribo, Milagros Fraga Pereira
Funding agency: Instituto de Salud Carlos III
Funding: 98615
Reference: PI15/00170
Duration: 01/01/2016 - 31/12/2019

Related news

A study conducted at the Catalan Multiple Sclerosis Centre (Cemcat) shows that the lack of a reduction in neurofilament light chain during the first year of treatment is associated with a higher risk of subsequent disease activity.

The project’s 4th annual meeting was recently held as part of the Fortalece–Salud programme of the Carlos III Health Institute.

An international study led by researchers from Vall d’Hebron shows that simple tests that patients can perform themselves help detect changes in disability that may occur even in the absence of disease relapses.

Related professionals

Guillem Sarró Cardelús

Guillem Sarró Cardelús

Gestió i Administració
Unidad de Proyectos Post-Award
Competitive Research Directorate
Read more
Magalí Sureda de la Fuente

Magalí Sureda de la Fuente

Research technician
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Patricia Pérez Badillo

Patricia Pérez Badillo

Research assistant
Multidisciplinary Nursing Research Group
Read more
Ferran Blasco Casado

Ferran Blasco Casado

Postdoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.